Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum

Takashi Seto, Takeharu Yamanaka, Makiko Nakano, Mayuko Ota, Riichiroh Maruyama, Tatsuro Okamoto, Hiroshi Wataya, Kazutsugu Uematsu, Nobuhiko Seki, Kenji Eguchi, Hiroshi Semba, Yukito Ichinose

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: An open-label, single-arm prospective study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine and tegafur-uracil (UFT) in patients with advanced nonsmall-cell lung cancer (NSCLC) after the failure of previous platinum-containing regimens. PATIENTS AND METHODS: Patients with advanced NSCLC received 200 mg/m of UFT twice daily from day 1 through 14 plus 900 mg/m of gemcitabine per day via intravenous injection on days 8 and 15. This regimen was repeated every 3 or 4 weeks. RESULTS: A total of 40 patients were enrolled. Eleven patients (28%; 95% confidence interval [CI], 15-44%) achieved a partial response. The median progression-free survival, median overall survival, and 1-year survival rate were 4.0 months (95% CI, 3.3-6.7 months), 12.6 months (95% CI, 7.0-22.3 months), and 51% (95% CI, 33-66%), respectively. The most common grade 3 or 4 toxicity was neutropenia (38%; 95% CI, 23-54%) and the rate of grade 3 or 4 nonhematologic toxicity remained at less than 5%. A multivariate Cox model showed that adenocarcinoma, nonsmoking history, and good performance status predicted better survival. CONCLUSIONS: Combination chemotherapy with UFT and gemcitabine showed a promising effectiveness and acceptable toxicity for patients with platinum-resistant NSCLC.

Original languageEnglish
Pages (from-to)637-642
Number of pages6
JournalJournal of Thoracic Oncology
Volume3
Issue number6
DOIs
Publication statusPublished - 2008 Jun

Fingerprint

gemcitabine
Tegafur
Uracil
Combination Drug Therapy
Platinum
Non-Small Cell Lung Carcinoma
Confidence Intervals
Survival
Neutropenia
Proportional Hazards Models
Intravenous Injections
Disease-Free Survival
Adenocarcinoma
Survival Rate
History
Prospective Studies

Keywords

  • Adenocarcinoma
  • Advanced nonsmall-cell lung cancer
  • Gemcitabine
  • Nonsmoking
  • Second-line chemotherapy
  • Tegafur-uracil

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum. / Seto, Takashi; Yamanaka, Takeharu; Nakano, Makiko; Ota, Mayuko; Maruyama, Riichiroh; Okamoto, Tatsuro; Wataya, Hiroshi; Uematsu, Kazutsugu; Seki, Nobuhiko; Eguchi, Kenji; Semba, Hiroshi; Ichinose, Yukito.

In: Journal of Thoracic Oncology, Vol. 3, No. 6, 06.2008, p. 637-642.

Research output: Contribution to journalArticle

Seto, T, Yamanaka, T, Nakano, M, Ota, M, Maruyama, R, Okamoto, T, Wataya, H, Uematsu, K, Seki, N, Eguchi, K, Semba, H & Ichinose, Y 2008, 'Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum', Journal of Thoracic Oncology, vol. 3, no. 6, pp. 637-642. https://doi.org/10.1097/JTO.0b013e318174e070
Seto, Takashi ; Yamanaka, Takeharu ; Nakano, Makiko ; Ota, Mayuko ; Maruyama, Riichiroh ; Okamoto, Tatsuro ; Wataya, Hiroshi ; Uematsu, Kazutsugu ; Seki, Nobuhiko ; Eguchi, Kenji ; Semba, Hiroshi ; Ichinose, Yukito. / Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum. In: Journal of Thoracic Oncology. 2008 ; Vol. 3, No. 6. pp. 637-642.
@article{0317789960e442d7866e84aeb427e5cf,
title = "Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum",
abstract = "BACKGROUND: An open-label, single-arm prospective study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine and tegafur-uracil (UFT) in patients with advanced nonsmall-cell lung cancer (NSCLC) after the failure of previous platinum-containing regimens. PATIENTS AND METHODS: Patients with advanced NSCLC received 200 mg/m of UFT twice daily from day 1 through 14 plus 900 mg/m of gemcitabine per day via intravenous injection on days 8 and 15. This regimen was repeated every 3 or 4 weeks. RESULTS: A total of 40 patients were enrolled. Eleven patients (28{\%}; 95{\%} confidence interval [CI], 15-44{\%}) achieved a partial response. The median progression-free survival, median overall survival, and 1-year survival rate were 4.0 months (95{\%} CI, 3.3-6.7 months), 12.6 months (95{\%} CI, 7.0-22.3 months), and 51{\%} (95{\%} CI, 33-66{\%}), respectively. The most common grade 3 or 4 toxicity was neutropenia (38{\%}; 95{\%} CI, 23-54{\%}) and the rate of grade 3 or 4 nonhematologic toxicity remained at less than 5{\%}. A multivariate Cox model showed that adenocarcinoma, nonsmoking history, and good performance status predicted better survival. CONCLUSIONS: Combination chemotherapy with UFT and gemcitabine showed a promising effectiveness and acceptable toxicity for patients with platinum-resistant NSCLC.",
keywords = "Adenocarcinoma, Advanced nonsmall-cell lung cancer, Gemcitabine, Nonsmoking, Second-line chemotherapy, Tegafur-uracil",
author = "Takashi Seto and Takeharu Yamanaka and Makiko Nakano and Mayuko Ota and Riichiroh Maruyama and Tatsuro Okamoto and Hiroshi Wataya and Kazutsugu Uematsu and Nobuhiko Seki and Kenji Eguchi and Hiroshi Semba and Yukito Ichinose",
year = "2008",
month = "6",
doi = "10.1097/JTO.0b013e318174e070",
language = "English",
volume = "3",
pages = "637--642",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",

}

TY - JOUR

T1 - Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum

AU - Seto, Takashi

AU - Yamanaka, Takeharu

AU - Nakano, Makiko

AU - Ota, Mayuko

AU - Maruyama, Riichiroh

AU - Okamoto, Tatsuro

AU - Wataya, Hiroshi

AU - Uematsu, Kazutsugu

AU - Seki, Nobuhiko

AU - Eguchi, Kenji

AU - Semba, Hiroshi

AU - Ichinose, Yukito

PY - 2008/6

Y1 - 2008/6

N2 - BACKGROUND: An open-label, single-arm prospective study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine and tegafur-uracil (UFT) in patients with advanced nonsmall-cell lung cancer (NSCLC) after the failure of previous platinum-containing regimens. PATIENTS AND METHODS: Patients with advanced NSCLC received 200 mg/m of UFT twice daily from day 1 through 14 plus 900 mg/m of gemcitabine per day via intravenous injection on days 8 and 15. This regimen was repeated every 3 or 4 weeks. RESULTS: A total of 40 patients were enrolled. Eleven patients (28%; 95% confidence interval [CI], 15-44%) achieved a partial response. The median progression-free survival, median overall survival, and 1-year survival rate were 4.0 months (95% CI, 3.3-6.7 months), 12.6 months (95% CI, 7.0-22.3 months), and 51% (95% CI, 33-66%), respectively. The most common grade 3 or 4 toxicity was neutropenia (38%; 95% CI, 23-54%) and the rate of grade 3 or 4 nonhematologic toxicity remained at less than 5%. A multivariate Cox model showed that adenocarcinoma, nonsmoking history, and good performance status predicted better survival. CONCLUSIONS: Combination chemotherapy with UFT and gemcitabine showed a promising effectiveness and acceptable toxicity for patients with platinum-resistant NSCLC.

AB - BACKGROUND: An open-label, single-arm prospective study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine and tegafur-uracil (UFT) in patients with advanced nonsmall-cell lung cancer (NSCLC) after the failure of previous platinum-containing regimens. PATIENTS AND METHODS: Patients with advanced NSCLC received 200 mg/m of UFT twice daily from day 1 through 14 plus 900 mg/m of gemcitabine per day via intravenous injection on days 8 and 15. This regimen was repeated every 3 or 4 weeks. RESULTS: A total of 40 patients were enrolled. Eleven patients (28%; 95% confidence interval [CI], 15-44%) achieved a partial response. The median progression-free survival, median overall survival, and 1-year survival rate were 4.0 months (95% CI, 3.3-6.7 months), 12.6 months (95% CI, 7.0-22.3 months), and 51% (95% CI, 33-66%), respectively. The most common grade 3 or 4 toxicity was neutropenia (38%; 95% CI, 23-54%) and the rate of grade 3 or 4 nonhematologic toxicity remained at less than 5%. A multivariate Cox model showed that adenocarcinoma, nonsmoking history, and good performance status predicted better survival. CONCLUSIONS: Combination chemotherapy with UFT and gemcitabine showed a promising effectiveness and acceptable toxicity for patients with platinum-resistant NSCLC.

KW - Adenocarcinoma

KW - Advanced nonsmall-cell lung cancer

KW - Gemcitabine

KW - Nonsmoking

KW - Second-line chemotherapy

KW - Tegafur-uracil

UR - http://www.scopus.com/inward/record.url?scp=44649142568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649142568&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318174e070

DO - 10.1097/JTO.0b013e318174e070

M3 - Article

C2 - 18520804

AN - SCOPUS:44649142568

VL - 3

SP - 637

EP - 642

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -